United Therapeutics Corp
UTHR
$494.63
-0.53%
United Therapeutics Corp is a biotechnology company focused on the development and commercialization of therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by high blood pressure in the lungs' arteries. Its core products include Tyvaso DPI, Remodulin, Orenitram, Adcirca, and Unituxin, with Tyvaso DPI being the largest revenue contributor. The company is a leader in the PAH space, with a portfolio largely based on the prostacyclin pathway and the molecule treprostinil, giving it a distinct competitive identity in a niche market. Current investor attention centers on the FDA's acceptance of the NDA for ralinepag, a potential new PAH therapy, and the competitive dynamics with Liquidia's Yutrepia, as well as the company's strong cash flow generation and share repurchase activity.…
UTHR
United Therapeutics Corp
$494.63
Related headlines
Investment Opinion: Should I buy UTHR Today?
We assign a Hold rating on UTHR, balancing its deep valuation discount and strong balance sheet against stalled revenue growth and margin compression. The analyst consensus is Buy with a mean rating of 1.64 and an average target price of $664.33, implying 33.6% upside, but the stock's recent underperformance and technical weakness suggest near-term caution. The core thesis is that UTHR is a cash-rich, undervalued biotech with a potential catalyst in ralinepag, but until revenue growth inflects, the stock may remain range-bound.
The supporting evidence for a Hold is compelling: UTHR trades at a trailing PE of 16.17, roughly half the biotechnology sector average of 30-40x, and EV/EBITDA of 11.03 is also below peers. The company generated $1.02 billion in TTM free cash flow and has a debt-to-equity ratio of just 0.0053, providing significant financial flexibility. However, revenue declined 1.62% year-over-year in Q1 2026, and gross margin fell to 82.9% from 88.4% a year ago, indicating operational headwinds. The stock's 3-month relative strength versus the S&P 500 is -11.99%, reflecting waning momentum.
The biggest risks that could invalidate the thesis include: (1) ralinepag failing to gain FDA approval or disappointing in commercialization, which would remove a key growth catalyst; (2) accelerated competition from Liquidia's Yutrepia eroding Tyvaso's market share and pricing power; and (3) continued margin compression leading to earnings misses. We would upgrade to Buy if the PE compresses below 14x or if ralinepag approval is accompanied by strong launch metrics, and downgrade to Sell if revenue growth turns negative for two consecutive quarters or if gross margin falls below 80%. Relative to its history and peers, UTHR appears undervalued, but the market is pricing in legitimate growth concerns, making it fairly valued at current levels until a catalyst emerges.
Sign up to view all
UTHR 12-Month Price Forecast
UTHR presents a classic value-versus-growth dilemma: the stock is statistically cheap with a PE of 16.17 and a PEG of 1.16, backed by a fortress balance sheet and massive buybacks, yet revenue has stalled and margins are compressing. The ralinepag NDA acceptance is a potential catalyst, but the market is skeptical given the stock's 22.68% underperformance versus the S&P 500 over 6 months. We maintain a neutral stance with medium confidence, as the risk/reward is balanced: the downside to the 52-week low of $396 is about 20%, while the upside to the analyst average target is 33.6%. We would upgrade to bullish if ralinepag approval is confirmed and early launch metrics show strong adoption, or if revenue growth turns positive for two consecutive quarters. Conversely, a downgrade to bearish would follow a Complete Response Letter for ralinepag or a significant loss of Tyvaso market share.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $664.33 and implied upside of +34.3% versus the current price.
Average Target
$664.33
0 analysts
Implied Upside
+34.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$515 - $725
Analyst target range
The stock is covered by 12 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.64, where 1 is Strong Buy and 5 is Strong Sell). The average target price is $664.33, implying an upside of 33.6% from the current price of $497.11. The consensus is bullish, with the majority of analysts rating it a Buy or Outperform, as evidenced by recent actions from firms like Wells Fargo (Overweight) and RBC Capital (Outperform).
The target price range is wide, from a low of $515 to a high of $725, indicating significant uncertainty. The high target of $725 likely assumes successful approval and commercialization of ralinepag, as well as expansion of Tyvaso into new indications, driving revenue growth and multiple expansion. The low target of $515, just 3.6% above the current price, may reflect concerns about competitive pressures from Liquidia's Yutrepia and potential margin erosion. The wide spread suggests that analysts have divergent views on the company's growth prospects, but the recent upgrade from Wells Fargo (from Equal Weight to Overweight) and the FDA acceptance of the ralinepag NDA are positive catalysts that could drive the stock toward the higher end of the range.
Bulls vs Bears: UTHR Investment Factors
The bull case rests on UTHR's deep valuation discount (PE 16.17 vs. sector 30-40x), fortress balance sheet, and the ralinepag NDA acceptance as a potential growth catalyst, supported by a consensus Buy rating and 33.6% upside to analyst targets. However, the bear case is equally compelling: revenue has stalled (-1.62% YoY), margins are compressing, and the stock is in a clear medium-term downtrend, underperforming the S&P 500 by 22.68% over 6 months. The most critical tension is whether ralinepag's approval and successful commercialization can reignite growth and reverse the margin decline, or whether competitive pressures from Liquidia's Yutrepia will further erode UTHR's franchise. Currently, the bear evidence has stronger near-term momentum, but the bull case has stronger fundamental underpinnings; the resolution of the ralinepag regulatory review is the single most important factor that will determine the stock's trajectory over the next 12 months.
Bullish
- Deep Value vs Biotech Peers: UTHR trades at a trailing PE of 16.17 and forward PE of 16.55, roughly half the biotechnology sector average of 30-40x. EV/EBITDA of 11.03 and PS of 6.78 are also well below industry norms, suggesting the market is pricing in stagnation that may not materialize if ralinepag is approved.
- Fortress Balance Sheet, Massive Buybacks: Debt-to-equity is just 0.0053 and the current ratio is 6.60, with $1.07 billion in cash. The company repurchased $1.5 billion of stock in Q1 2026 alone, reducing shares outstanding and signaling management's confidence in intrinsic value.
- Ralinepag NDA Accepted by FDA: The FDA accepted the NDA for ralinepag in PAH, a potential new therapy that could extend the company's franchise beyond treprostinil-based products. This catalyst could drive revenue growth and multiple expansion, with analysts' high target of $725 reflecting this optionality.
- Exceptional Profitability and Cash Flow: Gross margin of 82.9% and operating margin of 41.7% in Q1 2026 remain exceptionally high for biotech. TTM free cash flow of $1.02 billion provides ample resources to fund R&D and return capital without needing external financing.
Bearish
- Revenue Growth Has Stalled: Q1 2026 revenue of $781.5 million declined 1.62% year-over-year and 1.1% sequentially from Q4 2025. This plateau suggests maturing products and raises questions about the company's ability to grow organically without new approvals.
- Margin Compression Is Accelerating: Gross margin fell to 82.9% in Q1 2026 from 86.9% in Q4 2025 and 88.4% in Q1 2025. Operating margin also declined to 41.7% from 45.2% sequentially, indicating pricing pressure or rising costs that could erode profitability.
- Competitive Threat from Liquidia's Yutrepia: Liquidia's Yutrepia is gaining momentum in the PAH space, directly competing with UTHR's Tyvaso franchise. Intense competition could limit UTHR's pricing power and market share, as highlighted in recent Zacks analysis.
- Technical Breakdown and Underperformance: The stock is down 8.95% over 3 months and 7.28% over 6 months, underperforming the S&P 500 by 11.99% and 22.68% respectively. It sits at 45.6% of its 52-week range, with a series of lower highs since April, signaling negative momentum.
UTHR Technical Analysis
UTHR has experienced a mixed trend over the past year, with a 1-year price change of +22.79%, but recent weakness has pulled the stock down from its 52-week high of $609.35 to the current price of $497.11, which is only 16.6% above the 52-week low of $396.12. This places the stock in the lower half of its 52-week range, at approximately 45.6% of the range, suggesting that despite the positive annual return, momentum has faded and the stock is testing support levels. The 6-month change of -7.28% and 3-month change of -8.95% indicate a sustained downtrend in the medium term, contrasting with the longer-term gain.
Short-term momentum remains negative, with a 1-month price change of -2.86% and a 3-month decline of 8.95%, while the 1-year change is positive, creating a divergence that could signal a trend reversal or a prolonged consolidation. The relative strength versus the S&P 500 over the past year is +6.57%, but over the past 3 months, it is -11.99%, highlighting recent underperformance. The stock's beta of 0.558 indicates lower volatility than the broader market, which may appeal to risk-averse investors but also means it may lag in strong bull markets. The recent price action shows a series of lower highs and lower lows since April, with the stock now hovering near $497, down from $609 in March.
Key technical levels to watch include support at the 52-week low of $396.12 and resistance at the 52-week high of $609.35. A breakdown below the recent low of $487.61 (September 4) could accelerate selling pressure toward the $450 area, while a breakout above $530 would signal a potential reversal. The max drawdown of -18.29% over the past year reflects moderate risk, and with a beta of 0.558, the stock is less volatile than the market, but the current downtrend warrants caution. Volume of 573,357 shares is relatively light, which could exacerbate price swings on any news.
Beta
0.56
0.56x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$409-$609
Price range past year
Annual Return
+20.7%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -6.5% | -1.0% |
| 3m | -7.8% | +2.0% |
| 6m | -5.7% | +17.4% |
| 1y | +20.7% | +15.0% |
| ytd | -0.4% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
UTHR's revenue trajectory has been relatively flat, with the most recent quarter (Q1 2026) showing revenue of $781.5 million, a slight decline of 1.62% year-over-year from $794.4 million in Q1 2025. Sequentially, revenue decreased from $790.2 million in Q4 2025, indicating a possible plateau. The revenue mix is dominated by Tyvaso at $457.5 million, followed by Orenitram at $135.6 million and Remodulin at $126.6 million, while Unituxin and Adcirca contribute smaller amounts. The modest decline suggests maturing products, but the potential approval of ralinepag could reignite growth.
Profitability remains robust, with Q1 2026 net income of $274.9 million and a net margin of 35.2%, though this is down from 46.1% in Q4 2025. Gross margin stands at 82.9% in Q1 2026, lower than the 86.9% in Q4 2025 and 88.4% in Q1 2025, indicating some margin compression. Operating margin was 41.7% in Q1 2026, down from 45.2% in Q4 2025. Despite the decline, these margins are exceptionally high for the biotechnology industry, reflecting the pricing power of its rare disease therapies. The company remains highly profitable, but the trend of shrinking margins bears watching.
The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.0053 and a current ratio of 6.60, indicating minimal leverage and ample liquidity. Free cash flow for Q1 2026 was $362.5 million, and trailing twelve-month free cash flow is $1.02 billion, providing significant financial flexibility. Return on equity is 18.8%, and return on assets is 11.6%, demonstrating efficient capital use. The company has been actively repurchasing shares, with $1.5 billion repurchased in Q1 2026, returning capital to shareholders. With cash of $1.07 billion and no dividend, UTHR is well-positioned to fund research and development internally.
Quarterly Revenue
$781500000.0B
2026-03
Revenue YoY Growth
-1.6%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Since UTHR is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 16.17, while the forward PE is 16.55, suggesting that the market expects earnings to remain stable or slightly decline. The forward PE being slightly higher than the trailing PE implies that analysts anticipate a modest decrease in earnings, which contrasts with the typical growth expectation for a biotech company. The PEG ratio of 1.16 indicates that the stock is reasonably valued relative to its expected growth rate.
Compared to the biotechnology industry average, UTHR's PE of 16.17 is significantly lower than the sector's typical PE of 30-40x, representing a discount of approximately 50%. This discount may be justified by the company's slower revenue growth and reliance on a mature product portfolio, but it could also present a value opportunity if ralinepag is approved. The price-to-sales ratio of 6.78 and EV/EBITDA of 11.03 are also below industry averages, further suggesting undervaluation relative to peers.
Historically, UTHR's PE ratio has ranged from a low of 8.75 in Q1 2024 to a high of 24.14 in Q4 2022, with the current 16.17 falling in the middle of that range. The PS ratio of 6.78 is near the lower end of its historical range, which has seen levels above 30 in Q1 2026 (due to a different calculation basis) but generally between 15 and 25. The current valuation appears attractive relative to its own history, but the market may be pricing in risks such as competitive pressures and patent expirations.
PE
16.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on UTHR's revenue concentration and margin erosion. Tyvaso alone contributed $457.5 million, or 58.5% of Q1 2026 revenue, making the company highly dependent on a single product. Gross margin has declined from 88.4% in Q1 2025 to 82.9% in Q1 2026, and operating margin fell from 48.2% to 41.7% over the same period, indicating pricing pressure or rising costs. While the balance sheet is exceptionally strong with debt-to-equity of 0.0053 and $1.07 billion in cash, the company's growth has stalled, with Q1 2026 revenue declining 1.62% year-over-year. This combination of high concentration, margin compression, and flat growth creates earnings volatility risk if any single product faces competitive or regulatory setbacks.
Market and competitive risks are significant given UTHR's premium valuation relative to its growth prospects and the intensifying PAH competition. The stock trades at a trailing PE of 16.17, which is a discount to the sector, but the forward PE of 16.55 is slightly higher, implying expected earnings decline. The beta of 0.558 indicates lower volatility than the market, but the stock has underperformed the S&P 500 by 11.99% over 3 months and 22.68% over 6 months, suggesting sector rotation or loss of confidence. Liquidia's Yutrepia is gaining traction, and recent news highlights fierce competition that could limit UTHR's long-term growth. Additionally, the wide analyst target range ($515 to $725) reflects uncertainty, and any negative regulatory news on ralinepag could trigger a sharp sell-off.
A worst-case scenario would involve ralinepag failing to gain FDA approval or being commercialized with weak uptake, combined with accelerated market share loss to Yutrepia and further margin erosion. In this scenario, the stock could retest its 52-week low of $396.12, representing a 20.3% decline from the current price of $497.11. If the bear case fully materializes, including a revenue decline of 5-10% and PE compression to 12x, the stock could fall to the analyst low target of $515 (though that is above current price) or lower; however, the 52-week low of $396.12 is a more realistic downside anchor, implying a loss of approximately 20.3%. A more severe scenario, such as a complete loss of Tyvaso market share, could push the stock below $400, but that is less likely given the company's strong cash flow and buyback support.
FAQ
The key risks for UTHR include: (1) Financial/operational risk: revenue concentration in Tyvaso (58.5% of Q1 2026 revenue) and margin compression, with gross margin falling from 88.4% to 82.9% year-over-year. (2) Competitive risk: Liquidia's Yutrepia is gaining momentum in the PAH market, potentially eroding UTHR's market share and pricing power. (3) Regulatory risk: the FDA may reject or delay ralinepag, removing a key growth catalyst. (4) Market risk: the stock has a beta of 0.558, but it has underperformed the S&P 500 by 11.99% over 3 months, and further sector rotation could pressure the shares. The most severe risk is a combination of ralinepag failure and accelerated Tyvaso erosion, which could drive the stock to its 52-week low of $396.12.
Our 12-month forecast for UTHR includes three scenarios: a bull case with 30% probability targeting $664-$725, driven by ralinepag approval and successful launch; a base case with 50% probability targeting $550-$620, assuming gradual ralinepag uptake and stable Tyvaso sales; and a bear case with 20% probability targeting $396-$480, if ralinepag fails and competition intensifies. The base case is most likely, as it reflects the current trajectory of modest growth and stable margins. The key assumption is that ralinepag is approved but launches gradually, contributing less than $200 million in first-year sales. The analyst average target of $664.33 aligns with our bull case, but we believe the base case is more realistic given near-term headwinds.
UTHR appears undervalued relative to its peers and its own history. The trailing PE of 16.17 is significantly below the biotechnology sector average of 30-40x, and the PEG ratio of 1.16 suggests a reasonable price for its expected growth. The PS ratio of 6.78 and EV/EBITDA of 11.03 are also below industry averages. Historically, UTHR's PE has ranged from 8.75 to 24.14, placing the current multiple in the middle of that range. However, the market may be pricing in legitimate concerns about revenue stagnation and competitive threats, which justifies some discount. If ralinepag is approved and drives growth, the multiple could expand toward the higher end of its historical range, implying significant upside.
UTHR may be a good buy for value-oriented investors seeking exposure to a profitable biotech with a strong balance sheet and a potential catalyst. The stock trades at a trailing PE of 16.17, about half the sector average, and offers a 33.6% upside to the analyst average target of $664.33. However, revenue declined 1.62% year-over-year in Q1 2026, and the stock has underperformed the S&P 500 by 22.68% over 6 months, indicating near-term headwinds. The biggest downside risk is a failed ralinepag approval or accelerated competition from Yutrepia, which could push the stock toward its 52-week low of $396.12, a 20% decline. For risk-tolerant investors with a 12- to 18-month horizon, the risk/reward is balanced, but it is not a compelling buy until growth stabilizes.
UTHR is more suitable for long-term investment than short-term trading. The company is in a mature growth stage with a beta of 0.558, indicating lower volatility, and pays no dividend, so returns depend on capital appreciation. Earnings visibility is moderate, with analyst EPS estimates ranging from $44.06 to $59.33 for the next year, but the ralinepag catalyst could take 12-18 months to fully materialize. Short-term traders may find opportunities around FDA news or earnings, but the stock's recent downtrend and light volume (573,357 shares) increase risk. We recommend a minimum holding period of 12-18 months to allow for the ralinepag launch and potential revenue inflection. Long-term investors should monitor margin trends and competitive dynamics closely.